Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone propionate/formoterol k-haler medium strength versus high-dose ICS/LABA in uncontrolled persistent asthma
2020-000302-28Phase 4Terminated
- Sponsor
- Mundipharma
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in persistent asthma comparing Fluticasone propionate/formoterol k-haler medium dose with High-dose ICS/LABA escalation (2 arms). Primary endpoint: Change in ACQ-7 total score at week 24. Started May 2020; status: terminated.
02
Drugs
fluticasone propionateformoterol
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2020-000302-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000302-28.